GSK plc (GSK) Earnings History
Turnaround36 years of earnings data (1990–2025) · Recovering earnings after a multi-year decline
Loading earnings history...
GSK plc (GSK) Earnings Overview
As of October 3, 2026, GSK plc (GSK) reported trailing twelve-month net income of $4.82B, reflecting +124.2% year-over-year growth. The company earned $2.37 per diluted share over the past four quarters, with a net profit margin of 17.5%.
Looking at the long-term picture, GSK's 5-year EPS compound annual growth rate (CAGR) stands at -0.6%, signaling declining earnings. The company achieved its highest annual net income of $14.96B in fiscal 2022.
GSK plc maintains industry-leading profitability with a gross margin of 72.4%, operating margin of 25.5%, and net margin of 17.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including AZN ($10.45B net income, 17.5% margin), NVS ($12.76B net income, 25.6% margin), SNY ($3.96B net income, 16.7% margin), GSK has outperformed on profitability metrics. Compare GSK vs AZN →
GSK Earnings vs Peers
Earnings metrics vs comparable public companies
GSK Historical Earnings Data (1990–2025)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.72B | +122.0% | $8.34B | $2.78 | 17.5% | 25.5% |
| 2024 | $2.58B | -47.7% | $4.02B | $1.24 | 8.2% | 12.8% |
| 2023 | $4.93B | -67.1% | $6.75B | $2.40 | 16.2% | 22.2% |
| 2022 | $14.96B | +241.1% | $6.43B | $7.32 | 51.0% | 21.9% |
| 2021 | $4.38B | -23.7% | $4.36B | $2.70 | 17.8% | 17.6% |
| 2020 | $5.75B | +23.8% | $5.98B | $2.86 | 23.6% | 24.6% |
| 2019 | $4.64B | +28.2% | $6.96B | $2.32 | 13.8% | 20.6% |
| 2018 | $3.62B | +136.5% | $5.48B | $1.82 | 11.8% | 17.8% |
| 2017 | $1.53B | +68.0% | $4.09B | $0.78 | 5.1% | 13.5% |
| 2016 | $912M | -89.2% | $2.60B | $0.46 | 3.3% | 9.3% |
| 2015 | $8.42B | +205.6% | $10.32B | $4.30 | 35.2% | 43.1% |
| 2014 | $2.76B | -49.3% | $3.60B | $1.42 | 12.0% | 15.6% |
| 2013 | $5.44B | +20.8% | $7.03B | $2.76 | 20.5% | 26.5% |
| 2012 | $4.50B | -14.5% | $7.30B | $2.26 | 17.0% | 27.6% |
| 2011 | $5.26B | +222.0% | $7.81B | $2.58 | 19.2% | 28.5% |
| 2010 | $1.63B | -70.5% | $3.78B | $0.80 | 5.8% | 13.3% |
| 2009 | $5.53B | +20.2% | $8.43B | $2.70 | 19.5% | 29.7% |
| 2008 | $4.60B | -11.8% | $7.14B | $2.20 | 18.9% | 29.3% |
| 2007 | $5.22B | -3.1% | $7.94B | $2.34 | 23.0% | 34.9% |
| 2006 | $5.39B | +14.9% | $7.19B | $2.36 | 23.2% | 31.0% |
| 2005 | $4.69B | +20.0% | $6.86B | $2.04 | 21.6% | 31.7% |
| 2004 | $3.91B | -12.8% | $5.26B | $1.70 | 19.6% | 26.3% |
| 2003 | $4.48B | +13.8% | $6.38B | $1.92 | 20.9% | 29.8% |
| 2002 | $3.94B | +26.9% | $5.55B | $1.66 | 18.6% | 26.2% |
| 2001 | $3.10B | -25.5% | $6.10B | $1.26 | 15.1% | 29.7% |
| 2000 | $4.16B | +129.8% | $4.73B | $1.68 | 23.0% | 26.2% |
| 1999 | $1.81B | -1.4% | $2.63B | $1.24 | 21.3% | 30.9% |
| 1998 | $1.84B | -0.8% | $2.68B | $1.26 | 23.0% | 33.6% |
| 1997 | $1.85B | -7.4% | $2.82B | $1.28 | 23.2% | 35.4% |
| 1996 | $2.00B | +37.0% | $3.13B | $1.42 | 23.9% | 37.5% |
| 1995 | $1.46B | +40.3% | $2.38B | $1.12 | 13.9% | 22.7% |
| 1994 | $1.04B | -20.0% | $1.45B | $0.40 | 16.0% | 22.4% |
| 1993 | $1.30B | +7.6% | $1.82B | $1.06 | 23.0% | 32.1% |
| 1992 | $1.21B | +16.8% | $1.52B | $1.00 | 24.5% | 30.9% |
| 1991 | $1.03B | +17.3% | $1.29B | $0.86 | 25.2% | 31.4% |
| 1990 | $881M | - | $0 | $0.74 | 25.9% | 0.0% |
Download Data
Export GSK earnings history in CSV or JSON format
Free sign-in required to download data
GSK Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
36+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GSK — Frequently Asked Questions
Quick answers to the most common questions about buying GSK stock.
What is GSK earnings per share (EPS)?
GSK trailing twelve-month (TTM) diluted EPS is $2.37, reflecting +124.2% year-over-year growth. The 5-year EPS CAGR is -0.6%. Complete EPS history from 1990 to 2025 is available in the table on this page.
What is GSK plc's net income?
GSK plc (GSK) trailing twelve-month net income is $4.8B as of 2025. Earnings grew +124.2% year-over-year. GSK plc has been profitable for 36 consecutive years.
Is GSK profitable?
Yes, GSK is profitable with a TTM net income of $4.8B and a net profit margin of +17.5%. GSK plc has generated profits for 36 consecutive years.
What is GSK's earnings growth rate?
GSK compound annual EPS growth rates (CAGR): 1-Year: +124.2%, 3-Year: -27.6%, 5-Year: -0.6%, 10-Year: -4.3%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1990 to 2025.
What are GSK's profit margins?
GSK plc net profit margin is +17.5%, operating margin is +25.5%, and gross margin is +72.4%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +39.4%.
Is GSK growing earnings?
Yes, GSK earnings are accelerating — EPS growth of +124.2% exceeds the 5-year CAGR of -0.6%. TTM net income reached $4.8B. Earnings momentum is strengthening.
What was GSK's best earnings year?
GSK plc's highest annual net income on record is $15.0B, achieved in fiscal year 2022. Earnings history on this page spans 1990 to 2025 and includes all annual and quarterly figures.
What were GSK's earnings last quarter?
GSK's most recent reported quarter was Q2 2026. Net income was $435M with diluted EPS of $0.22. For a full breakdown of all quarters, see the quarterly earnings table on this page.